Big News for These 2 Diabetes Hopefuls

In what has so far been a huge day for health care news, we heard two important announcements in the type 2 diabetes space. Eli Lilly (NYSE: LLY  )  announced positive top-line data in its phase 3 trial of empagliflozin, which means the company will be retaining a potential diabetes blockbuster in its pipeline, something Eli Lilly needs as other big drugs are going over patent cliffs. Also, Johnson & Johnson (NYSE: JNJ  ) is taking its drug in the same space, Invokana, before an FDA advisory committee on Thursday. In this video, Motley Fool health care bureau chief Brenton Flynn tells us why these two drugs have such huge potential -- and what risks they face.

While you can certainly make huge gains in the pharmaceuticals space, there are other great plays in health care to make as well. The medical devices company Intuitive Surgical has been a longtime pick of Motley Fool superinvestor David Gardner, and has soared 1,002.94% since he recommended it in March 2005. David specializes in identifying game-changing companies like this long before others are keen to their disruptive potential, and he helps like-minded investors profit while Wall Street catches up. I invite you to learn more about how he picks his winners with a free, personal tour of his flagship service: Supernova. Inside, you'll discover the science behind his market-trouncing returns. Just click here now for instant access.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2182581, ~/Articles/ArticleHandler.aspx, 9/26/2016 10:08:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,123.49 -137.96 -0.76%
S&P 500 2,151.58 -13.11 -0.61%
NASD 5,265.56 -40.19 -0.76%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 9:45 AM
JNJ $117.92 Down -0.89 -0.75%
Johnson and Johnso… CAPS Rating: *****
LLY $80.60 Down -0.56 -0.69%
Eli Lilly and Co. CAPS Rating: ***
AZN $33.60 Down -0.37 -1.09%
AstraZeneca CAPS Rating: ****
BMY $55.80 Down -0.68 -1.21%
Bristol-Myers Squi… CAPS Rating: ****
MRK $62.24 Down -0.72 -1.14%
Merck and Co. CAPS Rating: ****